+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy



Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy



Anti-Cancer Drugs 23(3): 326-334



The aim of the present study is to evaluate the clinical and biological factors (including markers of angiogenesis) as potential predictors of prognosis and benefit from metronomic therapy in patients with advanced breast cancer (ABC). Recent data suggest antiangiogenic activity of metronomic therapy. The study population included 62 patients with pretreated ABC who received cyclophosphamide and methotrexate orally. Tumour samples were analysed by immunohistochemistry for HER2, Ki-67, thymidine phosphorylase (TP), vascular endothelial growth factor and vascular endothelial growth factor receptor. The results from immunohistochemical analysis and clinico-pathological variables were studied to test their potential association with benefit from metronomic therapy. The median overall survival, progression-free survival and survival postprogression were 7.1 (range 0.2-38.3), 2.6 (range 0.2-28.9) and 3 (range 0-34.2) months, respectively. Among the clinical variables, age, performance status and previous therapy with taxanes were significantly associated with outcomes. Among the molecular markers, TP was found to be associated with progression-free survival. Metronomic therapy is an effective choice for ABC. Young women with a more indolent disease had the greatest benefit from this treatment. TP tumour expression might aid decision making but these findings must be confirmed in larger prospective, properly designed studies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053138546

Download citation: RISBibTeXText

PMID: 22129512

DOI: 10.1097/CAD.0b013e32834e735a


Related references

Serum EGFR and Serum HER-2/neu Are Useful Predictive and Prognostic Markers in Metastatic Breast Cancer Patients Treated With Metronomic Chemotherapy. Breast Diseases: A Year Book Quarterly 19(2): 176-177, 2008

Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 110(3): 509-517, 2007

Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. Future Oncology 11(1): 107-119, 2015

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. British Journal of Cancer 77(12): 2267-2273, 1998

Prognostic and predictive factors in patients with advanced squamous cell head and neck cancer treated with induction chemotherapy and radiotherapy. EJC Supplements 1(5): S48, 2003

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. World Journal of Surgical Oncology 11: 307, 2014

Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. British Journal of Cancer 75(9): 1360-1367, 1997

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid. Bmc Cancer 11: 403, 2012

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clinical Cancer Research 15(24): 7652-7657, 2009

Prognostic factors and efficacy of treatment in locally advanced breast cancer patients treated by neoadjuvant chemotherapy, surgery and radiotherapy. Radiotherapy & Oncology 56(Supplement 1): S142, 2000

Analysis of prognostic factors in patients with locally advanced breast cancer treated with intra-arterial infusion chemotherapy as an induction therapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(8 Pt 2): 2910-2912, 1989

Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast 34: 83-88, 2017

Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy. Zhonghua Zhong Liu Za Zhi 39(3): 195-200, 2017

Second-Line Chemotherapy of Advanced Colorectal Cancer: Predictive and Prognostic Factors. Advances in Clinical and Experimental Medicine 25(4): 725-732, 2017

Predictive and prognostic value of ER-α36 expression in breast cancer patients treated with chemotherapy. Steroids 84: 11-16, 2014